Latest period
$0.00
YoY change
—
5Y CAGR
—
Peak year (2015)
$562.26K
Cumulative CapEx
$649.47K
CapEx history chart for Relmada Therapeutics (RLMD) from 2012 to 2025
Latest: $0.00
CapEx growth chart for Relmada Therapeutics (RLMD) from 2012 to 2025
Latest: -100.0%
CapEx history table for Relmada Therapeutics (RLMD) from 2012 to 2025
| 2025 | $0.00 | — | $0.00 | ||
| 2024 | $0.00 | -100.0% | −$4.00 | ||
| 2023 | $4.00 | — | +$4.00 | ||
| 2022 | $0.00 | — | $0.00 | ||
| 2021 | $0.00 | — | $0.00 | ||
| 2020 | $0.00 | — | $0.00 | ||
| 2019 | $0.00 | — | $0.00 | ||
| 2018 | $0.00 | -100.0% | −$12.39K | ||
| 2017 | $12.39K | -75.1% | −$37.30K | ||
| 2016 | $49.69K | -91.2% | −$512.57K | ||
| 2015 | $562.26K | +2310.4% | +$538.93K | ||
| 2014 | $23.33K | +1195.9% | +$21.53K | ||
| 2013 | $1.80K | — | +$1.80K | ||
| 2012 | $0.00 | — | — |
- 2025$0.00—
- 2024$0.00-100.0%
- 2023$4.00—
- 2022$0.00—
- 2021$0.00—
- 2020$0.00—
- 2019$0.00—
- 2018$0.00-100.0%
- 2017$12.39K-75.1%
- 2016$49.69K-91.2%
- 2015$562.26K+2310.4%
- 2014$23.33K+1195.9%
- 2013$1.80K—
- 2012$0.00—
CapEx values are taken from Relmada Therapeutics's reported cash flow statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About CapEx at Relmada Therapeutics (RLMD)
According to Relmada Therapeutics's latest reported financial statements, the company's current CapEx (TTM) is $0.00. Capital expenditures (CapEx) are cash outlays for property, plant, and equipment and other long-lived productive assets — reported on the cash flow statement under investing activities. CapEx funds future capacity (factories, data centers, software, machinery), so rising spend can signal investment in growth, while heavy CapEx reduces free cash flow available to shareholders. We display CapEx as a positive amount (the absolute cash outflow); compare with revenue to gauge capital intensity and with total assets for the asset-base context.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
As of the 2025 fiscal year, Relmada Therapeutics (RLMD) reported CapEx of $0.00.
Over 2015–2025 (10 years), Relmada Therapeutics CapEx expanded at a -100.0% compound annual rate, with a net decline across the window.
Relmada Therapeutics CapEx plunged from $562.26K in 2015 to $0.00 in 2025, a 100.0% drawdown.
The record annual CapEx stands at $562.26K, reached in 2015; the historical low of $0.00 was recorded in 2012.
Relmada Therapeutics Capital Expenditures by Year
Relmada Therapeutics Capital Expenditures 2025: $0.00
Relmada Therapeutics CapEx in 2025 was $0.00.
Relmada Therapeutics Capital Expenditures 2024: $0.00
Relmada Therapeutics posted CapEx of $0.00 in 2024, plunged 100.0% below 2023.
Relmada Therapeutics Capital Expenditures 2023: $4.00
Relmada Therapeutics CapEx in 2023 was $4.00.
Relmada Therapeutics Capital Expenditures 2022: $0.00
Relmada Therapeutics CapEx in 2022 was $0.00.
Relmada Therapeutics Capital Expenditures 2021: $0.00
Relmada Therapeutics CapEx in 2021 was $0.00.
See more financial history for Relmada Therapeutics (RLMD).
Sector peers by CapEx
Healthcare peers of Relmada Therapeutics (RLMD), ranked by their latest CapEx
| $14.05B | |
| $7.84B | |
| $4.83B | |
| $4.11B | |
| $3.62B | |
| $2.81B | |
| $1.86B | |
| $1.21B |
- $14.05B
- $7.84B
- $4.83B
- $4.11B
- $3.62B
- $2.81B
- $1.86B
- $1.21B
Frequently asked questions
Relmada Therapeutics (RLMD) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation